National outcomes of expedited discharge following esophagectomy for malignancy

Expedited discharge following esophagectomy is controversial due to concerns for higher readmissions and financial burden. The present study aimed to evaluate the association of expedited discharge with hospitalization costs and unplanned readmissions following esophagectomy for malignant lesions. A...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2024-02, Vol.19 (2), p.e0297470-e0297470
Main Authors: Ebrahimian, Shayan, Chervu, Nikhil, Hadaya, Joseph, Cho, Nam Yong, Kronen, Elsa, Sakowitz, Sara, Verma, Arjun, Bakhtiyar, Syed Shahyan, Sanaiha, Yas, Benharash, Peyman
Format: Article
Language:English
Subjects:
Adult
Esophagectomy - adverse effects
Esophagus
Evaluation
Female
Humans
Medical care
Morbidity
Neoplasms
Patient Discharge
Patient Readmission
Postoperative Complications - epidemiology
Postoperative Complications - etiology
Prospective Studies
Quality management
Retrospective Studies
Risk Factors
Surgery
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Expedited discharge following esophagectomy is controversial due to concerns for higher readmissions and financial burden. The present study aimed to evaluate the association of expedited discharge with hospitalization costs and unplanned readmissions following esophagectomy for malignant lesions. Adults undergoing elective esophagectomy for cancer were identified in the 2014-2019 Nationwide Readmissions Database. Patients discharged by postoperative day 7 were considered Expedited and others as Routine. Patients who did not survive to discharge or had major perioperative complications were excluded. Multivariable regression models were constructed to assess association of expedited discharge with index hospitalization costs as well as 30- and 90-day non-elective readmissions. Of 9,886 patients who met study criteria, 34.6% comprised the Expedited cohort. After adjustment, female sex (adjusted odds ratio [AOR] 0.71, p = 0.001) and increasing Elixhauser Comorbidity Index (AOR 0.88/point, p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0297470